ELAN Corporation FY2026 Q2 Earnings Report

Quick View

Executive Summary

In addition to increases in revenue and earnings, operating leverage from improved gross margin and restrained SG&A expenses resulted in Operating Income expanding at a pace exceeding the revenue growth rate. Revenue was ¥295.3B (¥268.4B in the previous year, YoY+10.0%), Operating Income was ¥26.4B (¥20.6B, YoY+28.3%), and Ordinary Income was ¥25.9B (¥20.3B, YoY+27.5%). Consolidated Net Income was ¥17.3B (¥13.8B, YoY+25.7%), of which Net Income attributable to owners of the parent was ¥17.4B (¥13.7B, YoY+27.2%). Earnings per share was ¥28.74 (¥22.61 in the previous year, YoY+27.1%). The primary reason earnings growth exceeded revenue growth was that the gross margin improved by 1.1pt to 22.6% (21.5% in the previous year), while the SG&A ratio declined slightly to 13.7% (13.8%).

Factors Affecting Performance

【Revenue】Revenue was ¥295.3B, representing YoY+10.0% growth. The Company operates primarily as a single business in the nursing care and medical-related sector. Although revenue by segment has not been disclosed because the importance of other segments is limited, expansion of the core business appears to have driven the increase in revenue.

【Profit and Loss】Operating Income was ¥26.4B, increasing YoY+28.3% and substantially exceeding the revenue growth rate. The gross margin improved by 1.1pt from 21.5% in the previous year to 22.6%, while the SG&A ratio declined slightly to 13.7% from 13.8%, resulting in a 1.2pt improvement in the Operating Income margin from 7.7% to 8.9%. Ordinary Income was ¥25.9B (YoY+27.5%). Factors reducing Operating Income included equity-method investment losses of ¥0.9B, foreign exchange losses of ¥0.1B, and interest expenses of ¥0.3B, partially offset by interest income of ¥0.4B. Consolidated Net Income was ¥17.3B (YoY+25.7%), while the portion attributable to owners of the parent was ¥17.4B (YoY+27.2%). The effective income tax burden was approximately 33%, virtually unchanged from approximately 32% in the previous year. Overall, the results reflect increases in both revenue and earnings, accompanied by profitability improvement, with earnings growth exceeding revenue growth.

Key Financial Indicators

【Profitability】The Operating Income margin improved by 1.2pt to 8.9% from 7.7% in the previous year, while the Net Income margin also increased to 5.9%. ROE was 11.0%, rising primarily as a result of the improvement in the Net Income margin.【Cash Flow Quality】The Company secured Operating Cash Flow (OCF) of ¥18.5B, equivalent to 1.06 times consolidated Net Income, indicating broadly consistent accounting earnings and cash generation. However, OCF was limited to 0.66 times EBITDA (approximately ¥27.9B), suggesting that changes in working capital somewhat constrained cash conversion efficiency.【Investment Efficiency】Capital expenditures of ¥3.7B were approximately 2.5 times depreciation expense of ¥1.5B, indicating that funds are being prioritized for growth investment. Property, plant and equipment increased substantially by +99.4% year on year, making progress in investment recovery a key focus going forward.【Financial Soundness】The Equity Ratio was 58.1% (54.3% in the previous year), while the current ratio was 164.4% and the quick ratio was 150.0%, maintaining ample liquidity. Interest-bearing debt was small relative to total assets, and the financial foundation remained conservative.

Cash Flow Analysis

OCF was ¥18.5B, increasing YoY+16.5% from ¥15.8B in the previous year and equivalent to 1.06 times consolidated Net Income of ¥17.3B. In terms of working capital, the decrease in inventories contributed positively by +¥2.9B, while the increase in trade receivables of -¥3.0B and the decrease in trade payables of -¥3.4B reduced cash conversion. After deducting ¥8.6B in income taxes paid, OCF was compressed from the subtotal of ¥27.0B to ¥18.5B. Investing Cash Flow was -¥3.7B, all of which represented capital expenditures, consistent with the increase in property, plant and equipment (+99.4% year on year). Financing Cash Flow was -¥9.5B, with dividend payments of ¥9.1B representing the primary outflow. As a result, free cash flow (OCF + Investing Cash Flow) was positive at ¥14.7B, a sufficient level to cover dividends and capital expenditures.

Quality of Earnings

The adjustments from Operating Income to Ordinary Income were primarily high non-recurring items, including equity-method investment losses of ¥0.9B, foreign exchange losses of ¥0.1B, and interest expenses of ¥0.3B. Accordingly, the improvement in the Operating Income margin (7.7%→8.9%), which reflects the earning power of the core business, is considered to be structurally driven. Non-operating income was primarily interest income of ¥0.4B and was small in scale. The difference between Ordinary Income and Operating Income was mainly attributable to the equity-method loss on the non-operating expense side. Comprehensive Income was ¥18.1B, and the difference from consolidated Net Income of ¥17.3B was primarily due to foreign currency translation adjustments of +¥0.8B. This reflects valuation differences arising from the translation of overseas-related assets into yen and does not distort the underlying profitability of the core business.

Earnings Forecast and Guidance

Against the full-year Company forecasts of Revenue of ¥608.0B, Operating Income of ¥50.0B, Ordinary Income of ¥50.0B, and Net Income attributable to owners of the parent of ¥32.0B, progress as of the first half was 48.6% for Revenue, 52.8% for Operating Income, 51.8% for Ordinary Income, and 54.3% for Net Income. Each was around or above the approximately 50% benchmark for the first half, with progress on profit indicators, particularly, ahead of revenue progress. No revisions were made to the earnings or dividend forecasts in these results. Whether the improvement in first-half profitability can be maintained from the second half onward will be key to achieving the full-year targets.

Shareholder Returns

The interim dividend was zero (¥0), while the full-year dividend forecast is ¥16, with a year-end lump-sum dividend payment planned. The Payout Ratio against the full-year EPS forecast of ¥52.81 is approximately 30.3%. First-half free cash flow of ¥14.7B exceeded dividend payments during the period of ¥9.1B. Together with the current low-leverage financial structure, this indicates a stable ability to secure funds for dividends.

Risk Factors

1. Working Capital Fluctuations and Cash Conversion Efficiency: During the first half, trade receivables increased by ¥3.0B and trade payables decreased by ¥3.4B, limiting OCF to 0.66 times EBITDA. Seasonal fluctuations in inventories and payment and collection terms could affect cash flow from the second half onward.

2. Factors Affecting Non-Operating Income and Expenses: Equity-method investment losses of ¥0.9B and foreign exchange losses of ¥0.1B reduced Ordinary Income. Because these items have limited correlation with operating performance, the range of future fluctuations in Ordinary Income may vary depending on the performance of equity-method affiliates and foreign exchange trends.

3. Dependence on Nursing Care and Medical-Related Regulations: The Company’s principal business is in the nursing care and medical-related sector, which has industry characteristics whereby regulatory changes, including revisions to medical service fees and nursing care fees, may affect gross margins and demand trends.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Profitability is below the industry median and is positioned near the lower bound of the IQR.

Growth and Capital Efficiency

The revenue growth rate is also below the industry median and is below the lower bound of the IQR.

※Source: Compiled by the Company

Key Takeaways from the Results

1. Operating Income growth of +28.3%, exceeding revenue growth of +10.0%, indicates the emergence of operating leverage resulting from gross margin improvement (22.6%, +1.1pt) and a decline in the SG&A ratio, demonstrating a qualitative improvement in the earnings structure.

2. First-half progress against the full-year guidance was 52.8% for Operating Income and 54.3% for Net Income, exceeding revenue progress of 48.6%, indicating that profit progress is ahead.

3. OCF was limited to 0.66 times EBITDA. Although free cash flow itself was positive at ¥14.7B, the working capital burden from the increase in trade receivables and decrease in trade payables has constrained cash conversion efficiency and requires monitoring from a cash flow quality perspective.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥352–¥373 at Cost of Equity ±1%, and ¥360–¥366 at ω±0.1.

Notes:

• Goodwill amortization of ¥2.0 per share has been added back to earnings (to account for a non-cash expense and comparability with IFRS companies).
• Net assets as of the quarter-end have been used (there is a timing difference relative to the full-year forecast).
• Because non-controlling interests are included in net assets, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---